Chronic Hepatitis B Treatment Today: Who Needs Antivirals, Tenofovir vs Entecavir, and Where Lamivudine Still Fits

🧬 A positive hepatitis B surface antigen test that is still positive six months later means chronic hepatitis B. For most people the next question is simple: do I need tablets, and if so, which ones? The honest answer is that many people with chronic hepatitis B do not need treatment yet, but all of them need regular checks. 🔍 Those who do need treatment today usually take one tablet a day of entecavir or tenofovir, drugs that keep the virus suppressed for years with very little resistance. Lamivudine, once the standard, is now rarely the first choice for hepatitis B alone, yet it still has a clear place in some situations.
🧬 What chronic hepatitis B really means
🦠 Hepatitis B virus infects liver cells and stores a stable copy of its genetic material, called cccDNA, inside their nucleus. That hidden copy is the reason current tablets suppress the virus but rarely remove it completely. An adult infected for the first time usually clears the virus: more than 90% of healthy adults recover from acute hepatitis B within a few months. A baby infected at birth is the opposite case: about 9 in 10 develop lifelong infection, which is why most chronic hepatitis B in the world began in infancy or early childhood.
📌 The liver damage comes mostly from the immune attack, not from the virus itself. Treatment cuts the supply of new virus so that this cycle quietens down.
🔄 The phases of chronic infection
📖 Chronic hepatitis B is not one steady state. It moves through phases, and the phase decides whether treatment helps. Doctors describe them using two markers: the e-antigen (HBeAg), which signals high viral activity, and the liver enzyme ALT, which shows inflammation.
| 📋 Phase | 🧪 Typical results | 💊 Usual approach |
|---|---|---|
| HBeAg-positive chronic infection (immune tolerant) | Very high HBV DNA, normal ALT, little scarring, often young people | Monitor; treat if over about 30 to 40, family history of cancer or fibrosis present |
| HBeAg-positive chronic hepatitis | High HBV DNA, raised ALT, active inflammation | Treatment usually advised |
| HBeAg-negative chronic infection (inactive carrier) | Low HBV DNA, often under 2,000 IU/mL, normal ALT | Monitor every 6 to 12 months |
| HBeAg-negative chronic hepatitis | HBV DNA above 2,000 IU/mL, raised or fluctuating ALT | Treatment usually advised, often long term |
| HBsAg-negative phase (resolved or occult) | Surface antigen gone, anti-HBc positive | No treatment; risk of reactivation with strong immunosuppression |
🔁 People can move back and forth between these phases, so a single normal result never ends follow-up.
🧪 The three numbers that decide treatment
🧮 Viral load, liver inflammation and liver scarring are read together, never one alone.
💡 ALT deserves a note. Laboratories often print a normal range up to 40 or 50 U/L, but several hepatitis B guidelines use stricter healthy limits of about 35 U/L for men and 25 U/L for women. An ALT the laboratory calls normal can still count as raised for hepatitis B decisions.
📏 Measuring liver scarring without a biopsy
🩻 A liver biopsy used to be routine. Today transient elastography (often called FibroScan) is the usual first step: a probe on the skin measures how stiff the liver is. Blood scores such as APRI and FIB-4 are used when it is not available.
✅ Who needs treatment now
📋 Cut-offs vary by guideline, and WHO guidance from 2024 widened eligibility. The common core is to treat anyone whose liver is being damaged or is at high risk of damage.
⏸️ Who can safely wait
🕒 People in the inactive carrier phase, with low viral load, normal ALT and a soft liver, have a low risk of liver damage. For them, tablets add side effects and cost without a clear gain, so monitoring is the treatment. Waiting stays safe only while the checks continue.
🎯 What treatment can and cannot achieve
📉 Oral antivirals block the enzyme the virus uses to copy itself. Within months most patients reach an undetectable viral load and ALT returns to normal. Over years, even established fibrosis and some cirrhosis can partly regress.
Undetectable HBV DNA, normal ALT, slower or reversed scarring
Loss of HBeAg and formation of anti-HBe
Loss of surface antigen (functional cure), about 1% per year on tablets
🔬 Loss of the surface antigen, called functional cure, is the goal researchers are chasing with new drugs. For now, most people who start tablets should expect to take them for many years, often for life.
💊 First-line drug one: entecavir
💊 Entecavir is a nucleoside analogue that has been a first-choice drug for hepatitis B since the late 2000s. In people who have never taken lamivudine, resistance after five years is around 1%. The usual adult dose is 0.5 mg once daily, taken on an empty stomach, at least 2 hours after a meal and 2 hours before the next one.
- 📌 Side effects: usually mild, such as headache, tiredness, dizziness and nausea
- 📌 Rare but serious: lactic acidosis, mainly in people with advanced cirrhosis
- 📌 Kidneys: dose interval is extended when creatinine clearance falls below about 50 mL/min
- 📌 Pregnancy: not the preferred choice, as safety data are limited compared with tenofovir
💊 First-line drug two: tenofovir (TDF and TAF)
🧪 Tenofovir comes in two forms. Tenofovir disoproxil fumarate (TDF) 300 mg once daily has the longest record; tenofovir alafenamide (TAF) 25 mg once daily, taken with food, delivers the drug to liver cells at a much lower dose. No consistent tenofovir resistance has been confirmed in hepatitis B after many years of use.
⚖️ Entecavir or tenofovir: how doctors choose
🤔 Both drugs suppress the virus equally well in most people. The choice usually comes down to kidneys, bones, pregnancy plans and previous drug exposure.
📉 Why lamivudine fell from first choice
🕰️ Lamivudine, approved for hepatitis B in 1998, was the first oral drug. Its weakness is a low genetic barrier: a single mutation in the viral polymerase, known as the YMDD mutation, is enough to make the virus resistant. Resistance means viral load climbs again and ALT can flare.
🧩 Where lamivudine still fits today
💬 It remains a cheap, well-tolerated drug with real activity against both hepatitis B and HIV, and it still has several roles.
⚠️ Always test for HIV before starting lamivudine for hepatitis B. The hepatitis B dose of 100 mg is too low for HIV and, given alone, lets HIV quickly become resistant to lamivudine and related drugs. In anyone with HIV, lamivudine must only be part of a full HIV regimen.
🔗 Hepatitis B with HIV: one regimen for two viruses
🧬 The rule is simple: the HIV regimen must contain tenofovir, usually with lamivudine or emtricitabine, so that hepatitis B gets two active drugs. A fixed-dose tablet such as Viropil (Dolutegravir + Lamivudine + Tenofovir) covers this in one daily tablet.
| 💊 HIV medicine | 🦠 Activity against hepatitis B | 📝 Note for coinfection |
|---|---|---|
| Tenofovir (TDF or TAF) | Strong | Should be part of the regimen |
| Lamivudine | Yes, but resistance builds alone | Partner to tenofovir, not a substitute |
| Dolutegravir — Xapavir (Dolutegravir) | None | Two-drug dolutegravir plus lamivudine regimens are not advised with hepatitis B |
| Zidovudine — Retrovir (Zidovudine) | None | Adds nothing for the liver |
| Lamivudine with zidovudine — Combivir (Lamivudine + Zidovudine) | Lamivudine only | Hepatitis B is left on one drug; tenofovir usually added or preferred |
📖 If you are about to start HIV treatment, the first regimen and first year are explained in starting HIV treatment. Switching an HIV regimen when hepatitis B is present needs special care, as covered in HIV regimens, switching and drug resistance: dropping tenofovir can trigger a hepatitis B flare.
💉 Peginterferon: the finite-course option
📆 Peginterferon alfa is a weekly injection given for 48 weeks. It works by boosting the immune response rather than blocking the virus directly, and its main appeal is a fixed end date with a better chance of lasting response in selected patients. The best candidates are younger people with raised ALT, lower viral load and no cirrhosis.
🤒 The downside is side effects: flu-like symptoms, low mood, low blood counts and thyroid problems. It is not used in decompensated cirrhosis or pregnancy.
🩸 Before the first tablet: baseline tests
🧪 Testing for hepatitis C matters because the two infections interact. Hepatitis C is curable with tablets such as Hepcinat (Sofosbuvir) and Hepcvir (Sofosbuvir) combined with a second antiviral, but in people who also carry hepatitis B, clearing hepatitis C can wake the hepatitis B virus up. More on hepatitis C treatment: is effective hepatitis C treatment within reach for everyone.
📅 Monitoring on treatment
📋 Once tablets start, monitoring checks that the virus is falling, that the drug is safe and that no resistance appears. Missed doses are the most common reason for a viral load that stops falling.
🫘 Kidneys, bones and dose adjustments
🦴 All the oral hepatitis B drugs leave the body through the kidneys. Entecavir, TDF and lamivudine all need a dose or interval change when creatinine clearance drops below about 50 mL/min. TDF can, over years, reduce kidney filtration, cause phosphate loss and thin the bones slightly; in people at risk, doctors prefer entecavir or TAF.
| 🚫 Situation | 📝 What doctors usually do |
|---|---|
| Chronic kidney disease | Adjust dose; prefer entecavir or TAF over TDF |
| Osteoporosis or past fragility fracture | Avoid TDF when another option exists |
| Regular NSAID use | Review pain treatment; check kidney tests more often |
| Decompensated cirrhosis | Treat promptly, watch for lactic acidosis, refer to a liver unit |
🎗️ Liver cancer surveillance
🔎 Hepatitis B can cause liver cancer even without cirrhosis, because the virus can insert its DNA into liver cells. Surveillance means an ultrasound every 6 months, often with an alpha-fetoprotein blood test, for people at higher risk. Small tumours found this way can often be cured.
💡 Surveillance continues even when the viral load is undetectable.
⚠️ Stopping treatment and hepatitis flares
🔥 Every oral hepatitis B drug carries a warning about severe flares after stopping. When the tablet is stopped, the virus restarts from the cccDNA reservoir within weeks, and the immune attack that follows can cause a sharp ALT rise or even liver failure. The danger is highest in people with cirrhosis, in whom stopping is not advised at all.
Feels fine; virus starts to return
HBV DNA rises sharply
ALT flare, possible jaundice
Settles, or treatment must restart
📋 Planned stopping is possible in some people without cirrhosis: for example, after HBeAg loss followed by at least a year of consolidation treatment, or after loss of the surface antigen. Any planned stop needs blood tests every 1 to 3 months for at least the first year and a clear plan to restart if a flare begins.
🛡️ Reactivation: chemotherapy, biologics and hepatitis C cure
💉 Even people whose hepatitis B looks resolved, with surface antigen gone but anti-HBc positive, can see the virus return when the immune system is suppressed. Rituximab and similar drugs that remove B cells carry the highest risk, followed by stem cell transplant, high-dose steroids and some chemotherapy.
📖 Living with long-term immune-suppressing medicines and the checks they require is covered in living on immunosuppressants: monitoring, infection and vaccines. The same caution applies to hepatitis C cure: everyone starting hepatitis C tablets should be tested for hepatitis B first, and people with active hepatitis B usually receive an antiviral alongside.
🤰 Pregnancy: protecting the mother
👶 Hepatitis B does not usually stop a healthy pregnancy, and most women with it have healthy babies. All pregnant women should be tested for HBsAg early in pregnancy, and those who are positive need an HBV DNA test, ALT and a check of liver scarring. A woman already on entecavir or TAF who becomes pregnant should not stop, but ask about switching to TDF.
📌 Flares are most likely in the months after delivery, so ALT is checked again within 3 to 6 months after birth.
👶 Preventing passing it to the baby
🛡️ Without prevention, a baby born to a mother with HBeAg and a high viral load has a very high chance of lifelong infection, up to about 9 in 10. With a vaccine dose at birth, hepatitis B immunoglobulin and, when the viral load is high, tenofovir in late pregnancy, most of these infections are prevented.
🍼 Breastfeeding is allowed when the baby has received the vaccine and immunoglobulin, including while the mother takes TDF, as only small amounts pass into milk.
🏠 Daily life: alcohol, household and vaccines
🍺 Alcohol and extra weight both speed up liver scarring in hepatitis B, so the most useful lifestyle step is to drink little or nothing; the wider benefits are listed in the most important benefits of giving up alcohol.
Partners and people living in the home should be tested and vaccinated if not immune
Do not share razors, toothbrushes or nail scissors
Hugging, sharing meals and cutlery do not spread it
Herbal liver products and high-dose supplements can harm the liver; ask first
💉 Vaccination against hepatitis A is advised if not immune, since a second liver infection can be serious.
🗿 Myths about hepatitis B treatment
🚨 When to see a doctor
⛔ Seek medical help urgently if you have hepatitis B and notice:
🔹 Yellow skin or eyes, dark urine or pale stools.
🔹 Swelling of the abdomen or legs, vomiting blood or black stools.
🔹 New confusion, unusual sleepiness or easy bruising.
🔹 Severe tiredness, nausea or pain under the right ribs after stopping or missing antiviral tablets.
🔹 A positive pregnancy test, a planned course of chemotherapy, steroids or biologics, or a new HIV diagnosis: tell the doctor who manages your hepatitis B before anything changes.
❓ Frequently asked questions
Does everyone with chronic hepatitis B need treatment?
No. Treatment is advised when the liver is inflamed or scarred, or the risk is high. Inactive carriers usually need only regular blood tests and liver scans.
What are the first-line drugs for hepatitis B?
Entecavir and tenofovir, either TDF or TAF. Both suppress the virus strongly and resistance is rare even after years of use.
Why is lamivudine no longer first choice for hepatitis B?
The virus becomes resistant to it easily, in up to about 70% of patients within five years. It is still used in HIV coinfection with tenofovir and in some other situations.
What viral load needs treatment?
Treatment discussions usually start above 2,000 IU/mL when ALT is raised or fibrosis is present. With cirrhosis, any detectable virus is treated.
How long do I need to take hepatitis B tablets?
Usually for many years and often for life. Some people without cirrhosis can stop under close supervision after specific milestones.
What happens if I stop hepatitis B treatment suddenly?
The virus returns within weeks and can cause a severe hepatitis flare, which is especially dangerous with cirrhosis. Never stop without your doctor.
Can hepatitis B be cured?
Current tablets suppress the virus but rarely clear the surface antigen, which happens in about 1% of patients per year. New curative drugs are being studied.
Which hepatitis B drug is safe in pregnancy?
Tenofovir disoproxil fumarate (TDF) has the most safety data and is the preferred drug in pregnancy.
How is hepatitis B passing to the baby prevented?
The baby gets the hepatitis B vaccine and immunoglobulin at birth, and mothers with a high viral load take tenofovir from about week 24 to 28.
Can I breastfeed if I have hepatitis B?
Yes, once the baby has had the vaccine and immunoglobulin at birth, including while taking tenofovir.
📑 Sources and editorial
- 📘 International and regional clinical guidelines on prevention, diagnosis and treatment of chronic hepatitis B
- 🧬 Long-term cohort studies of entecavir and tenofovir in chronic hepatitis B, including resistance data
- 💊 Prescribing information and boxed warnings for lamivudine, entecavir and tenofovir
- 🔗 Guidelines on antiretroviral therapy in people with HIV and hepatitis B coinfection
- 🤰 Guidance on preventing mother-to-child transmission of hepatitis B
- 🛡️ Reviews of hepatitis B reactivation with immunosuppressive therapy and hepatitis C antivirals
- 📖 Related reading: starting HIV treatment, HIV regimens and drug resistance, living on immunosuppressants, hepatitis C treatment
- 🛒 Related products: Epivir (Lamivudine), Viropil (Dolutegravir + Lamivudine + Tenofovir), Combivir (Lamivudine + Zidovudine), Hepcinat (Sofosbuvir), Hepcvir (Sofosbuvir)
- 🩺 RXshop Editorial Team — reviewed by Emily Chen, MD — Internal Medicine
Medical Disclaimer: The information in this article is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from a qualified healthcare provider with any questions you may have regarding a medical condition, and before starting, stopping or changing any medication.